By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharma Receives Additional Non-Dilutive Funding From The Government Of Canada To Support Expanded Research With Lead Product Candidate VAL-083 1/9/2017 9:30:51 AM
DelMar Pharma Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083 12/14/2016 6:52:06 AM
DelMar Pharma Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting 11/21/2016 9:09:29 AM
DelMar Pharma Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update 11/14/2016 11:32:39 AM
DelMar Pharma Announces Upcoming Scientific Conference Presentations 10/13/2016 9:33:49 AM
DelMar Pharma Presents Data Supporting The Potential Of VAL-083 As A New Treatment For Ovarian Cancer At The 11th Biennial Ovarian Cancer Research Symposium 9/13/2016 8:54:49 AM
DelMar Pharma And Accurexa To Collaborate In The Development Of A Novel Combination Chemotherapy For The Local Treatment Of Brain Cancer 9/7/2016 9:02:25 AM
DelMar Pharma To Present At The 18th Annual Rodman & Renshaw Global Investment Conference On September 13, 2016 8/30/2016 11:28:33 AM
DelMar Pharma To Present At The 11th Biennial Ovarian Cancer Research Symposium 8/11/2016 11:29:49 AM
DelMar Pharma Announces Presentation At The European Association Of Neuro-Oncology (EANO) Annual Meeting In October 2016 7/21/2016 7:53:53 AM